Solid OAD2 Composition with Antioxidants for Storage Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of the small molecule GLP-1 receptor agonist OAD2 dihydrochloride are prone to rapid oxidative degradation, leading to high impurity growth and stability issues under normal storage conditions, which poses risks during drug administration.
Innovation Solution
The development of pharmaceutical compositions comprising OAD2 or its pharmaceutically acceptable salts, optimized with selected solubilizing agents and disintegrating agents that minimize reactive oxygen species and impurity formation, ensuring stable production and effective control of related substances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations of OAD2 dihydrochloride are used, then the drug can be administered, but rapid oxidative degradation occurs leading to high impurity growth and stability issues
Solution Approach 1:
The patent introduces antioxidants (such as ascorbic acid, tocopherol, or their derivatives) as intermediary substances that actively scavenge reactive oxygen species and prevent oxidative degradation of OAD2 dihydrochloride. These antioxidants serve as mediators between the drug substance and environmental oxygen, sacrificing themselves to protect the active ingredient from oxidation, thereby significantly reducing impurity B formation and improving formulation stability.
2Ease of operation
If the formulation is stored under normal conditions, then storage is convenient, but impurity growth is rapid and stability is compromised
Solution Approach 1:
The patent incorporates antioxidants and oxygen-scavenging materials into the formulation during manufacturing, performing preliminary protective action before the formulation is exposed to storage conditions. This pre-built defense system allows the formulation to be stored under normal conditions without requiring special storage environments, while simultaneously maintaining stability by preventing oxidative degradation from occurring in the first place.
3Productivity
If solubilizing agents and disintegrating agents are used to improve dissolution, then dissolution performance improves, but reactive oxygen species formation increases leading to impurity growth
Solution Approach 1:
The patent introduces antioxidants as intermediary substances that specifically target and neutralize reactive oxygen species generated during dissolution. These antioxidants are incorporated into the formulation alongside solubilizing agents and disintegrating agents, creating a protective chemical environment that allows these functional excipients to perform their dissolution-enhancing roles without generating harmful oxidative byproducts, thus maintaining both dissolution performance and chemical stability.
Data Source
AI summary
Provided in the present invention is a pharmaceutical composition of a small molecular GLP-1R receptor agonist suitable for oral administration. More specifically, the present invention relates to a pharmaceutical composition containing (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinoline-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propanoic acid (“OAD2”) and a pharmaceutically acceptable salt thereof, and a preparation method therefor. The composition may contain a low level of one or more oxidative degradation substances or may contain a low level of reactive oxygen species. The pharmaceutical composition provided in the present invention has low content of oxidative degradation impurity B and a low total impurity content, so that the composition can be stably stored for 12 months or more under normal temperature and normal humidity. The present invention further relates to a method for treating type II diabetes and indications related to improper blood glucose control using such pharmaceutical compositions.